Abstract
Midkine (MK) is a member of midkine family which is composed of MK and pleotrophin (PTN). MK behaves like a cytokine and growth factor, promotes the proliferation, differentiation, survival, adhesion, migration of cells. MK expression usually increases during ischemia, inflammation, tissue repair, neoplastic transformation and in different toxic conditions. Immune cells and most of organs have MK secretion function in fetal and adult life. MK could be a promising prognostic/diagnostic marker and a potential target in many of diseases including malignancy, toxic and inflammatory diseases. This review focuses on both cell protective and immune-modulatory roles of MK in different in vitro and in vivo disease models and human reports. MK is still a novel molecule in the regulation of organ development and the etiology of many diseases.
Keywords: Cytokine, immune system, inflammatory diseases, midkine, toxicity
Current Drug Delivery
Title:Midkine in Inflammatory and Toxic Conditions
Volume: 10 Issue: 1
Author(s): Nuray Yazihan
Affiliation:
Keywords: Cytokine, immune system, inflammatory diseases, midkine, toxicity
Abstract: Midkine (MK) is a member of midkine family which is composed of MK and pleotrophin (PTN). MK behaves like a cytokine and growth factor, promotes the proliferation, differentiation, survival, adhesion, migration of cells. MK expression usually increases during ischemia, inflammation, tissue repair, neoplastic transformation and in different toxic conditions. Immune cells and most of organs have MK secretion function in fetal and adult life. MK could be a promising prognostic/diagnostic marker and a potential target in many of diseases including malignancy, toxic and inflammatory diseases. This review focuses on both cell protective and immune-modulatory roles of MK in different in vitro and in vivo disease models and human reports. MK is still a novel molecule in the regulation of organ development and the etiology of many diseases.
Export Options
About this article
Cite this article as:
Yazihan Nuray, Midkine in Inflammatory and Toxic Conditions, Current Drug Delivery 2013; 10 (1) . https://dx.doi.org/10.2174/1567201811310010009
DOI https://dx.doi.org/10.2174/1567201811310010009 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential Impact of Sirtuin 1 Protein on Premature Ovarian Insufficiency
Current Proteomics Ghrelin Receptor Signaling: A Promising Therapeutic Target for Metabolic Syndrome and Cognitive Dysfunction
CNS & Neurological Disorders - Drug Targets Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design NF-κB as a Key Mediator of Brain Inflammation in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry Involvement of Hypoxia-Inducible Factors in the Dysregulation of Oxygen Homeostasis in Sepsis
Cardiovascular & Hematological Disorders-Drug Targets Renal and Urological Diseases of the Newborn Neonatal Acute Kidney Injury
Current Pediatric Reviews Myocardial Expression of TNF-α, IL-1β, IL-6, IL-8, IL-10 and MCP-1 After a Single MDMA Dose Administered in a Rat Model
Current Pharmaceutical Biotechnology Pharmaceutical Aspects of Hemoglobin-Based Oxygen Carriers
Current Drug Delivery Brief Daily Episode of Normoxia Inhibits Cardioprotection Conferred by Chronic Continuous Hypoxia. Role of Oxidative Stress and BK<sub>Ca</sub> Channels
Current Pharmaceutical Design Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology Modification of Decoy Oligodeoxynucleotides to Achieve the Stability and Therapeutic Efficacy
Current Topics in Medicinal Chemistry The Role of Calcium Handling Mechanisms in Reperfusion Injury
Current Pharmaceutical Design Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Neuroprotective Role of Hypothermia in Hypoxic-ischemic Brain Injury: Combined Therapies using Estrogen
Current Neuropharmacology Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids
Current Medicinal Chemistry Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Appraisal of Nano-Lipidic Astaxanthin cum Thermoreversible Gel and its Efficacy in Haloperidol Induced Parkinsonism
Current Drug Delivery Oligonucleotide-Based Molecular Therapy for Restenosis after Angioplasty
Current Drug Targets